113 related articles for article (PubMed ID: 32394076)
1. A meta-analysis of efficacy and safety of S-1 monotherapy or combination therapy as first-line treatment in metastatic colorectal cancer.
Wang Z; Wang MM; Zhou WL; Ye CY; Dai WP; Liu XL; Zhang GM; Cheng GL; Zang YS
Int J Colorectal Dis; 2020 Aug; 35(8):1567-1574. PubMed ID: 32394076
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Feng Z; Yan P; Hou X; Feng J; He X; Yang K
Ann Palliat Med; 2020 May; 9(3):883-894. PubMed ID: 32389017
[TBL] [Abstract][Full Text] [Related]
3. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
Derksen JWG; Smit KC; May AM; Punt CJA
Eur J Cancer; 2022 May; 166():73-86. PubMed ID: 35279472
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
Chen J; Wang J; Xu T
Medicine (Baltimore); 2019 Jul; 98(30):e16667. PubMed ID: 31348323
[TBL] [Abstract][Full Text] [Related]
7. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
[TBL] [Abstract][Full Text] [Related]
9. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials.
Yin W; Pei G; Liu G; Huang L; Gao S; Feng X
Oncotarget; 2015 Nov; 6(36):39365-72. PubMed ID: 26420815
[TBL] [Abstract][Full Text] [Related]
11. Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis.
Hu Y; Chen P; Xiang F
J Oncol; 2023; 2023():8740221. PubMed ID: 36816360
[TBL] [Abstract][Full Text] [Related]
12. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
Fan Q; Lv W; Xu Y; Dong Y; Xiang Z; Wang J
Curr Pharm Des; 2020; 26(26):3171-3186. PubMed ID: 32067605
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis.
Zhao G; Gao P; Yang KH; Tian JH; Ma B
Colorectal Dis; 2010 Jul; 12(7):615-23. PubMed ID: 19486086
[TBL] [Abstract][Full Text] [Related]
14. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
Cao Y; Liao C; Tan A; Liu L; Mo Z; Gao F
Colorectal Dis; 2010 Jan; 12(1):16-23. PubMed ID: 19220378
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
Hu W; Xu WS; Liao XF; He HJ
Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis.
Chen J; Wang J
Medicine (Baltimore); 2019 Jun; 98(23):e15999. PubMed ID: 31169742
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
[TBL] [Abstract][Full Text] [Related]
20. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis.
Kawai S; Takeshima N; Hayasaka Y; Notsu A; Yamazaki M; Kawabata T; Yamazaki K; Mori K; Yasui H
BMC Cancer; 2021 Feb; 21(1):116. PubMed ID: 33541293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
